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Objectives. We investigated expression of brain natriuretic
peptide (BNP) as well as atrial natriuretic peptide (ANP) and
their genes in human right atria. Their relations with atrial
pressure were also examined.
Background. The BNP plays a roll in electrolyte-fluid ho-
meostasis such as ANP. The tissue level is reported to be elevated
in the failing ventricles. However, expression and transmural
distribution of BNP in the atria remain unclear.
Methods. Expression of ANP and BNP was immunohistochemi-
cally investigated in the right atrial (RA) specimens from 21
patients who had undergone cardiac surgery. The mRNA of
specimens were quantitatively measured by Northern blot analy-
sis and also evaluated by in situ hybridization. In addition,
plasma levels of ANP and BNP were measured in the patients.
Results. The BNP immunoreactivity was diffusely seen in RA
tissue of patients with mean RA pressure (mRAP) of 5 mm Hg or
more, but it was noted only in the subendocardial half of the atria
of those with mRAP less than 5 mm Hg. There was a significant
correlation between the incidence of BNP-positive myocytes and
mRAP (r 5 0.850, p < 0.0001). Conversely, ANP-positive myocytes
were found diffusely in all cases. In Northern blot analysis, the
mRNAs levels of ANP and BNP in the atrial tissue were positively
correlated with the mRAP (ANP, p 5 0.775, p < 0.005 and BNP,
p 5 0.771, p < 0.005). In situ hybridization confirmed these
findings. The mRNA levels were significantly correlated to each
other (r 5 0.845, p < 0.0002). Plasma ANP and BNP levels were
elevated in the patients compared with that in controls; however,
none were significantly correlated with the mRAP.
Conclusions. Expression of BNP and BNP mRNA is augmented
in the atria with increased pressure, and distributed predomi-
nantly in the subendocardial side. The level of BNP mRNA was
well correlated with that of ANP mRNA. Thus, these two genes
might be commonly regulated in response to atrial pressure.
(J Am Coll Cardiol 1998;32:1832–8)
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Brain natriuretic peptide (BNP) shares biological and struc-
tural similarities with atrial natriuretic peptide (ANP) (1–3).
Both appear to play a role in fluid-electrolyte homeostasis
(3–5) and are produced in hearts of various animals and
humans (2,3). The major source of circulating BNP is thought
to be ventricular myocytes (6) and that of circulating ANP is
atrial myocytes (6,7). Plasma ANP level and atrial ANP
expression are known to be augmented in patients with atrial
hemodynamic overload (e.g., mitral stenosis and atrial septal
defect) (8). In ventricle, both ANP and BNP are overex-
pressed, being correlated with severity of congestive heart
failure (CHF) or ventricular hemodynamic overload (6,9–12).
Contrary to these findings, expression of BNP in human atria
has not been well elucidated. Furthermore, the relationship
between expression of BNP in the atria and atrial hemodynam-
ics has not been investigated in humans.
In the present study, we investigated the expression and
tissue localization of both peptides (ANP and BNP) in human
right atrial (RA) appendages obtained at surgery, using immu-
nohistochemistry, Northern blot analysis, and in situ hybrid-
ization. We also measured plasma levels of both peptides with
radioimmunoassay. The relation between expression of these
peptide and hemodynamic parameters, especially mean right
atrial pressure (mRAP), was clarified.
Methods
Patients’ profiles. Specimens were obtained from 21 pa-
tients during cardiac surgery (11 males and 10 females, mean
age 59 6 11 years) (Table 1): 3 patients with atrial septal
defect, 2 with mitral stenosis, 1 with mitral regurgitation, 1 with
aortic regurgitation, 1 with aortic stenosis, 10 with angina
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pectoris (n 5 6) and/or old myocardial infarction (n 5 4), 2
with aortic aneurysm and 1 with left atrial myxoma. Two
patients were in New York Heart Association (NYHA) func-
tional class IV, 4 in class III, 12 in class II, and 2 in class I. The
NYHA class was evaluated on the day of catheterization.
Patients were hemodynamically stable during 15 6 7 days
between catheterization and operation, and there was no
change in therapeutic regimens during that period. All patients
had restriction of dietary sodium intake less than 10 g/day, and
all medications were stopped on the days of catheterization
and operation.
Informed consent was obtained from each patient. This
study was approved by the ethical committee on human
research of Kyoto University.
Tissue preparation. Specimens were obtained from the
cannulation site in the RA appendage before starting extra-
corporeal circulation. Sampling site was the same because of
surgical maneuver. For immunohistochemistry and in situ
hybridization, specimens were fixed in paraformaldehyde and
embedded in OCT-compound (Miles, Elkhart, Indiana) and
stored at 270°C. Specimens for RNA analysis were obtained
from 12 of 21 patients (three with atrial septal defect, two with
mitral stenosis, one with mitral regurgitation, five with angina
pectoris, one with left atrial myxoma), frozen and stored at
270°C until use.
Immunohistochemistry. Sections were stained by the indi-
rect immunoperoxidase method using antibodies against ANP
and BNP as reported previously (9,12–15). Evaluation of
immunohistological findings were carried out by two individu-
als independently and who did not know patient information
such as diagnosis and hemodynamic parameters. To grade the
immunostaining of BNP, we used a semiquantitative scoring
system as follows: BNP-positive and -negative myocytes were
counted in 20 random high-power fields (HPF, 3200) in a
subendocardial half and epicardial half in each specimen, and
percent ratio of BNP-positive myocytes to total count of
myocytes was calculated (BNP score).
Northern blot analysis. Total cellular RNA was prepared
using single-step RNA extraction (16). Human ANP cDNA
(17) and human BNP cDNA (18) probes were labeled with
[alpha]-32P-dCTP using random-priming method. The radio-
activity of hybridized band was measured using a BAS analyz-
ing system (Fuji Film, Japan). The mean value of RA-specific
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1 MS 60F 4 8 10 10 76 78 1.82 3.39 diff diff 42.3 128.4
2 Myx 66F 4 5 6 8 58 66 0.94 0.75 diff diff – –
3 MR 58F 3 7 8 9 83 68 1.47 0.52 diff diff 63.9 125.8
4 ASD 61F 3 7 6 8 55 58 1.98 2.89 diff diff 64.8 41.9
5 MS 58M 3 5 4 10 58 79 1.74 2.06 diff diff 62.0 143.6
6 OMI 62M 3 5 6 20 44 48 – – subend subend 137.6 245.6
7 ASD 38F 2 5 6 11 62 55 0.48 0.51 subend subend 29.4 17.0
8 ASD 51M 2 5 5 10 59 58 0.88 0.83 diff diff – –
9 OMI 54M 2 5 7 17 35 45 – – subend subend 54.2 151.2
10 AP 56M 2 4 6 12 57 33 0.32 0.36 subend subend 30.9 17.9
11 AP 62M 2 4 6 11 66 38 0.32 0.36 subend subend 18.0 26.4
12 AR 62F 2 4 4 8 87 34 – – diff subend 42.0 50.1
13 AP 49F 2 3 4 10 58 25 0.86 0.28 subend subend 15.5 18.2
14 AP 69F 2 3 4 9 66 22 0.42 0.36 subend subend 24.6 14.3
15 AP 52M 2 3 3 12 55 23 0.75 0.17 subend subend 15.9 4.3
16 AS 68F 2 3 5 12 74 25 – – subend subend – –
17 AP 77M 2 3 4 10 77 19 – – subend subend 45.6 81.3
18 AP 79M 2 2 3 5 63 31 – – subend subend 24.6 13.8
19 OMI 72M 2 – – 12 66 22 – – subend subend 38.4 23.4
20 AA 64M 1 – – – – 11 – – subend subend 13.5 14.2
21 AA 39F 1 – – – – 13 – – subend subend 11.9 13.5
Pt, patient; Dx, diagnosis; NYHA, New York Heart Association functional class; mRAP, mean right atrial pressure; LVEDP, left ventricular end-diastolic pressure;
LVEF, left ventricular ejection fraction; a.u., arbitrary unit; MS, mitral stenosis; Myx, myoxoma; MR, mitral regurgitation; ASD, atrial septal defect; OMI, old
myocardial infarction; AP, angina pectoris; AR, aortic regurgitation; AS, aortic stenosis; AA, aortic aneurysm; diff, diffuse; subend, subendocardial; –, not measured.
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mRNA level normalized by beta-2-microglobulin cDNA (19)
was arbitrarily set as 1.0 for each mRNA species.
Digoxigenin-labeled riboprobes and in situ hybridization.
Human ANP and BNP cDNA probes used in the Northern
blot were subcloned into pBluescript SK2 (Stratagene,
La Jolla, California) and pCR ™II (Invitrogen, Carlsbad,
California), respectively. Riboprobes were transcribed using
digoxigenin-labeled dUTP (Boehringer Mannheim, Germany)
with an appropriate RNA polymerase (19).
In situ hybridization for ANP mRNA and BNP mRNA was
performed on cryosections according to the method previously
reported (20).
Measurement of plasma levels of ANP and BNP. Plasma
was sampled in 18 of the study patients and 5 normal control
subjects. Blood was sampled at 6:00 AM while the subjects were
fasting in a recumbent position. Measurement was performed
with radioimmunoassay as previously reported (6,7).
Statistical analysis. We set the cutoff point of the mRAP
at 5 mm Hg. This was based on the mRAP of 2 to 4 mm Hg
(3 6 1 mm Hg), which was calculated from 31 normal control
subjects (17 men and 14 women). They underwent cardiac
catheterization because of chest pain, minimal ECG changes
or arrhythmias, but examinations revealed no specific abnor-
malities.
Data were expressed as the mean 6 SD. Statistical com-
parisons were performed using unpaired t test and chi-square
test appropriately. Selected variables were compared using
linear regression analysis. Multiple regression analysis was
used to determine correlations between the results. Statistical
significance was designated as a probability of less than 0.05.
Results
Immunohistochemical expression of ANP and BNP. In all
the sections examined, ANP immunoreactivity was evident in
the cytoplasm of all myocytes, and definite difference in its
distribution and intensity was not found (Fig. 1, A, B, and G).
Conversely, BNP immunoreactivity was relatively weaker than
ANP immunoreactivity (Fig. 1, D). The BNP immunostaining
showed a transmural gradient from subendocardium to epicar-
dium (Fig. 1, C and D). In cases with mRAP of 5 mm Hg or
more, BNP-positive myocytes were seen diffusely from suben-
docardium to subepicardium (Fig. 1, E and F). The BNP score
is listed in Table 1. This value of immunoreactive BNP was
positively correlated with mRAP (r 5 0.850, p , 0.0001) (Fig.
2).
Northern blot analysis. The radioactivity of the hybridized
band of beta-2-microglobulin was similar in each case and was
not correlated with the mRAP (Fig. 3). Atrial mRNA levels of
BNP and ANP normalized by beta-2-microglobulin were cor-
related positively with the mRAP (ANP mRNA: r 5 0.775, p ,
0.005 and BNP mRNA: r 5 0.771, p , 0.005) (Fig. 4, A and B)
Figure 1. Photomicrographs showing immunohistochemistry of ANP
and BNP in human right atrial appendage (panels A through H). Note
that panels A and C, panels B and D are serial sections from patient
14 in Table 1, panels E, F, G and H are serial sections from patient 1
in Table 1. Panels A and B show epicardial and endocardial side,
respectively, in a section stained with anti-ANP antibody. Panels C and
D, and panels E and F also show epicardial side and endocardial side,
respectively, in each section stained with anti-BNP antibody. ANP-
positive myocytes (brown staining) were seen from subendocardium
(panel B) to subepicardium (panel A). The BNP-positive myocytes
were seen in the subendocardial side of the atrial wall (panel D), and
were not seen in subepicardial side (panel C) in patient 14. However,
in patient 1, BNP-positive myocytes were seen in the subepicardial side
as well as in the subendocardial side (panels E and F). Panel G (a
serial section of panel E) shows ANP immunostaining. A control
section (a serial section of panels E and G) incubated with anti-BNP
antibody preabsorbed with BNP (panel H) showed no immunoreac-
tivity. Asterisks and arrowheads indicates epicardial side and endocar-
dial side, respectively. Original magnification was 3200 (panels A
through H).
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and they were correlated with each other (r 5 0.845, p ,
0.0002) (Fig. 4, C).
In situ hybridization of BNP and ANP. Signals of in situ
hybridization were dark precipitates in the cytoplasm (Fig. 5, A
to E). Hybridization signals of ANP and BNP mRNA were
distributed like immunoreactive BNP. The mRNA signals of
ANP and BNP were found only in the subendocardial half of
the atria in patients with mRAP less than 5 mm Hg (Fig. 5, A
and B). In those with mRAP of 5 mm Hg or more, signals
showed diffuse and transmural distribution (Fig. 5, C to E).
Plasma levels of ANP and BNP. The plasma levels of ANP
and BNP in the study patients (n 5 18) were 40.8 6 30.0 and
62.8 6 68.1 pg/ml, respectively, which were significantly higher
Figure 2. Plots showing the relationship between the mean right atrial
pressure (mRAP) and immunostaining of brain natriuretic peptide
(BNP). The BNP-scores of the atria were well correlated with mRAP
(p , 0.01). See text regarding the BNP score.
Figure 3. Representative Northern blot showing mRNA levels of
ANP, BNP and beta-2-microglobulin (BMG). Two mg and 5 mg of total
RNA per lane were hybridized with 32P-labeled ANP and BNP cDNA
probes, respectively, and they were rehybridized with 32P-labeled BMG
cDNA probes. Mean right atrial pressure (mRAP) of each patient was
indicated above the lane number (lane 1 through 5). Lane 1, patient 15
in Table 1; lane 2, patient 13; lane 3, patient 8; lane 4, patient 3; lane
5, patient 1, respectively.
Figure 4. Panel A: Plots showing a positive correlation between the
right atrial mRNA levels of ANP (ANP mRNA) and mean right atrial
pressure (mRAP). Panel B: Plots showing a positive correlation
between the right atrial mRNA levels of BNP (BNP mRNA) and the
mRAP. Panel C: Plots showing a positive correlation between the
levels of ANP mRNA and BNP mRNA.
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than those in normal control subjects (n 5 5); the plasma levels
of ANP and BNP were 19.2 6 5.9 and 6.6 6 2.7 pg/ml,
respectively. We performed multiple regression analysis to
assess the degree to which one of the hemodynamic parame-
ters (mRAP, right ventricular end-diastolic pressure, left ven-
tricular end-diastolic pressure, and ejection fraction) was as-
sociated with the plasma levels of ANP and BNP. Among
them, the left ventricular end-diastolic pressure showed signif-
icant relations with the plasma ANP and BNP levels (Table 2).
However, no statistically significant relation was identified
between the mRAP and plasma levels of ANP and BNP.
Discussion
Expression of BNP in human right atria. In the present
study, we have shown expression of BNP by immunohisto-
chemistry and that of BNP mRNA by Northern blot analysis
and in situ hybridization in human RA tissue. We examined
them in the right atrial appendage. As reported by Rodeheffer
et al. (21), atrial appendage is representative of the whole atria
on ANP expression in normal and failing hearts. However,
investigations in other parts of the atria as well as in the
appendage might be desirable. We did not evaluate the
expression of ANP and BNP in the left atria, either, which is
also to be further examined.
The BNP-positive myocytes were predominantly localized
in the atrial subendocardial region. Semiquantitative measure-
ment by BNP score confirmed this. According to in situ
hybridization, the mRNA signals of BNP showed a distribution
pattern similar to the immunostaining of BNP. We previously
showed a transmural gradient of BNP expression in the
porcine normal atria (13). In the present study, we have
evidenced a transmural gradient of BNP at both peptide and
gene levels in human right atrial wall.
Regulatory mechanisms for BNP expression in the atria.
Different from the predominant expression of BNP in the
subendocardial side of RA in patients with mRAP less than
5 mm Hg, BNP-positive myocytes were found diffusely in the
atrial wall in patients with mRAP of 5 mm Hg or more. The
BNP mRNA was also increased in these patients. There was a
positive correlation between BNP score and mRAP and be-
tween the level of BNP mRNA and mRAP. We also found a
positive correlation between BNP mRNA and ANP mRNA.
These suggest that synthesis of BNP and ANP in human right
atria may be commonly associated with atrial pressure.
Increased intracavitary pressure generally accompanies
augmentation of wall stress (Laplace’s law). The expression of
ANP and BNP is augmented in the left ventricles of the failing
hearts (6,7,9–12,18,22) or in the ventricles of hypertrophic
cardiomyopathy without CHF (14,23). In these reports, in-
creased wall stress and local stress are supposed to evoke the
expression of the ANP and BNP genes in the left ventricles. In
fact, wall stress decreases from the endocardial side to the
epicardial side (24,25). Therefore, this regulation mechanism
of natriuretic peptides in the ventricle would also work in the
atria.
Wall stress generally induces wall stretch at physiological
states. Atrial stretch causes secretion of ANP from atria of
Figure 5. Photomicrographs showing in situ hybridization
of ANP mRNA and BNP mRNA. Hybridization signals
were dark precipitates in the cytoplasm. Panels A and B:
serial sections. No hybridization signal was found in any
connective tissue or vasculature. The BNP mRNA signals
were found only in the subendocardial myocytes of the
atria with mRAP less than 5 mm Hg (panel A), whereas
they were found diffusely and transmurally in the atria with
mRAP of 5 mm Hg or more (panels C and E). The ANP
mRNA signals were also found in a similar distribution;
they were found either in the subendocardial myocytes of
the atria with lower mRAP (panel B) or diffusely and
transmurally in those with higher mRAP (panel D). A
control section (a serial section of panel E) incubated with
digoxigenin-labeled sense riboprobes of BNP showed no
signals (panel F). Asterisks and arrowheads indicate epi-
cardial and endocardial side, respectively. Original magni-
fication was 3200 (panels A through E).
Table 2. Correlation Coefficients Relating Hemodynamic






r-Value p-Value r-Value p-Value
mRAP (mm Hg) 0.440 0.1016 0.494 0.0606
RVEDP (mm Hg) 0.347 0.2096 0.453 0.0905
LVEDP (mm Hg) 0.594 0.0180* 0.647 0.0077*
EF (%) 20.272 0.3338 20.240 0.3968
*Statistically significant. See Table 1 for abbreviations.
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experimental models (26). Atrial stretch is also reported to
cause increase of ANP mRNA levels in the cultured atrial
myocytes (27). However, it is controversial whether BNP
synthesis is enhanced by stretch (26,28). Although the present
study apparently included patients with right atrial dilatation,
we did not analyze relationship between dilatation (stretch)
and synthesis of natriuretic peptides because any appropriate,
established methods are not available at present for evaluating
right atrial volume. A link between stretch and BNP synthesis
needs to be further elucidated.
Although all medications were halted on the days of
catheterization and operation, we do not believe their influ-
ences can be completely negligible. However, we did not
analyze the influence of the drugs on expression and excretion
of ANP and BNP. The strict analysis was impossible because
varing amounts and combinations of many drugs had been
given to the patients according to their clinical states. There
are many reports on the pharmacologic effects of drugs such as
angiotensin-converting enzyme inhibitors (29,30), nitroglycerin
(31), calcium antagonists (32) and adrenergic blockers (33) on
the excretion of ANP and/or BNP. However, few studies report
their effects on the tissue expression of ANP and BNP. Thus,
further analyses are expected in this field.
Atrial contribution to systemic natriuretic peptide levels.
Circulating ANP and BNP levels and atrial mRNA expression
of these peptide were increased in patients with atrial septal
defect and mitral stenosis in the present study. In these
patients, right ventricular overload was seen, in addition to
atrial overload. It is well-known that right ventricular overload
increases ANP and BNP expression in the right ventricles
(6,34). We performed multiple regression analysis to assess the
degree to which of the hemodynamic parameters, mRAP in
particular, was associated with the plasma levels of ANP and
BNP. We found significant correlations only in the left ven-
tricular end-diastolic pressure, but not in mRAP. This suggests
that the right atrial secretion of ANP and BNP does not
contribute significantly to the systemic levels in the study
patients. However, it is possible that left atria may have been a
far larger source of the peptides in some patients studied.
Thus, the present analysis may have underestimated the over-
all atrial contribution to circulating levels of ANP and BNP
because of a lack of information regarding left atria. In
addition, an analysis is necessary to confirm the present result,
using a larger patient population accompanied by higher
mRAP.
Augmentation of BNP expression in the right atria with
increased mRAP may be one of the compensatory mechanisms
of hearts against volume overload when considering the phar-
macological effects of BNP such as vasodilation and natriuresis
(1–5), but the lack of relationship between plasma level of BNP
and mRAP indirectly suggests that the compensation by atrial
BNP is incomplete. Such an incomplete compensation may
justify the clinical use of exogenous natriuretic peptides.
Conclusions. The present study revealed the following
findings. First, immunoreactive BNP and mRNA signals of
BNP showed the transmural gradient in the atria. Second, the
atrial expression of BNP was augmented in response to the
increased atrial pressure and was well correlated with the
mRAP. Third, atrial expression of BNP mRNA was well
correlated with that of ANP mRNA. Thus, these two genes
may share some common regulatory mechanisms, and atrial
pressure was suggested to be one of them.
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